275 results on '"Jonathan H. Chung"'
Search Results
2. Early-stage COVID-19 pandemic observations on pulmonary embolism using nationwide multi-institutional data harvesting
- Author
-
Axel Wismüller, Adora M. DSouza, Anas Z. Abidin, M. Ali Vosoughi, Christopher Gange, Isabel O. Cortopassi, Gracijela Bozovic, Alexander A. Bankier, Kiran Batra, Yosef Chodakiewitz, Yin Xi, Christopher T. Whitlow, Janardhana Ponnatapura, Gary J. Wendt, Eric P. Weinberg, Larry Stockmaster, David A. Shrier, Min Chul Shin, Roshan Modi, Hao Steven Lo, Seth Kligerman, Aws Hamid, Lewis D. Hahn, Glenn M. Garcia, Jonathan H. Chung, Talissa Altes, Suhny Abbara, and Anna S. Bader
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
Abstract We introduce a multi-institutional data harvesting (MIDH) method for longitudinal observation of medical imaging utilization and reporting. By tracking both large-scale utilization and clinical imaging results data, the MIDH approach is targeted at measuring surrogates for important disease-related observational quantities over time. To quantitatively investigate its clinical applicability, we performed a retrospective multi-institutional study encompassing 13 healthcare systems throughout the United States before and after the 2020 COVID-19 pandemic. Using repurposed software infrastructure of a commercial AI-based image analysis service, we harvested data on medical imaging service requests and radiology reports for 40,037 computed tomography pulmonary angiograms (CTPA) to evaluate for pulmonary embolism (PE). Specifically, we compared two 70-day observational periods, namely (i) a pre-pandemic control period from 11/25/2019 through 2/2/2020, and (ii) a period during the early COVID-19 pandemic from 3/8/2020 through 5/16/2020. Natural language processing (NLP) on final radiology reports served as the ground truth for identifying positive PE cases, where we found an NLP accuracy of 98% for classifying radiology reports as positive or negative for PE based on a manual review of 2,400 radiology reports. Fewer CTPA exams were performed during the early COVID-19 pandemic than during the pre-pandemic period (9806 vs. 12,106). However, the PE positivity rate was significantly higher (11.6 vs. 9.9%, p
- Published
- 2022
- Full Text
- View/download PDF
3. Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative ‐ Group 3 Pulmonary Hypertension
- Author
-
Lucilla Piccari, Brian Allwood, Katerina Antoniou, Jonathan H. Chung, Paul M. Hassoun, Sylvia M. Nikkho, Rajan Saggar, Oksana A. Shlobin, Patrizio Vitulo, Steven D. Nathan, and Stephen John Wort
- Subjects
endophenotype ,histology ,idiopathic pulmonary fibrosis ,pathophysiology ,pulmonary vascular disease ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Pulmonary hypertension (PH) is a frequent complication of interstitial lung disease (ILD). Although PH has mostly been described in idiopathic pulmonary fibrosis, it can manifest in association with many other forms of ILD. Associated pathogenetic mechanisms are complex and incompletely understood but there is evidence of disruption of molecular and genetic pathways, with panvascular histopathologic changes, multiple pathophysiologic sequelae, and profound clinical ramifications. While there are some recognized clinical phenotypes such as combined pulmonary fibrosis and emphysema and some possible phenotypes such as connective tissue disease associated with ILD and PH, the identification of further phenotypes of PH in ILD has thus far proven elusive. This statement reviews the current evidence on the pathogenesis, recognized patterns, and useful diagnostic tools to detect phenotypes of PH in ILD. Distinct phenotypes warrant recognition if they are characterized through either a distinct presentation, clinical course, or treatment response. Furthermore, we propose a set of recommendations for future studies that might enable the recognition of new phenotypes.
- Published
- 2023
- Full Text
- View/download PDF
4. The genomics of heart failure: design and rationale of the HERMES consortium
- Author
-
R. Thomas Lumbers, Sonia Shah, Honghuang Lin, Tomasz Czuba, Albert Henry, Daniel I. Swerdlow, Anders Mälarstig, Charlotte Andersson, Niek Verweij, Michael V. Holmes, Johan Ärnlöv, Per Svensson, Harry Hemingway, Neneh Sallah, Peter Almgren, Krishna G. Aragam, Geraldine Asselin, Joshua D. Backman, Mary L. Biggs, Heather L. Bloom, Eric Boersma, Jeffrey Brandimarto, Michael R. Brown, Hans‐Peter Brunner‐La Rocca, David J. Carey, Mark D. Chaffin, Daniel I. Chasman, Olympe Chazara, Xing Chen, Xu Chen, Jonathan H. Chung, William Chutkow, John G.F. Cleland, James P. Cook, Simon deDenus, Abbas Dehghan, Graciela E. Delgado, Spiros Denaxas, Alexander S. Doney, Marcus Dörr, Samuel C. Dudley, Gunnar Engström, Tõnu Esko, Ghazaleh Fatemifar, Stephan B. Felix, Chris Finan, Ian Ford, Francoise Fougerousse, René Fouodjio, Mohsen Ghanbari, Sahar Ghasemi, Vilmantas Giedraitis, Franco Giulianini, John S. Gottdiener, Stefan Gross, Daníel F. Guðbjartsson, Hongsheng Gui, Rebecca Gutmann, Christopher M. Haggerty, Pim van derHarst, Åsa K. Hedman, Anna Helgadottir, Hans Hillege, Craig L. Hyde, Jaison Jacob, J. Wouter Jukema, Frederick Kamanu, Isabella Kardys, Maryam Kavousi, Kay‐Tee Khaw, Marcus E. Kleber, Lars Køber, Andrea Koekemoer, Bill Kraus, Karoline Kuchenbaecker, Claudia Langenberg, Lars Lind, Cecilia M. Lindgren, Barry London, Luca A. Lotta, Ruth C. Lovering, Jian'an Luan, Patrik Magnusson, Anubha Mahajan, Douglas Mann, Kenneth B. Margulies, Nicholas A. Marston, Winfried März, John J.V. McMurray, Olle Melander, Giorgio Melloni, Ify R. Mordi, Michael P. Morley, Andrew D. Morris, Andrew P. Morris, Alanna C. Morrison, Michael W. Nagle, Christopher P. Nelson, Christopher Newton‐Cheh, Alexander Niessner, Teemu Niiranen, Christoph Nowak, Michelle L. O'Donoghue, Anjali T. Owens, Colin N.A. Palmer, Guillaume Paré, Markus Perola, Louis‐Philippe Lemieux Perreault, Eliana Portilla‐Fernandez, Bruce M. Psaty, Kenneth M. Rice, Paul M. Ridker, Simon P.R. Romaine, Carolina Roselli, Jerome I. Rotter, Christian T. Ruff, Marc S. Sabatine, Perttu Salo, Veikko Salomaa, Jessica vanSetten, Alaa A. Shalaby, Diane T. Smelser, Nicholas L. Smith, Kari Stefansson, Steen Stender, David J. Stott, Garðar Sveinbjörnsson, Mari‐Liis Tammesoo, Jean‐Claude Tardif, Kent D. Taylor, Maris Teder‐Laving, Alexander Teumer, Guðmundur Thorgeirsson, Unnur Thorsteinsdottir, Christian Torp‐Pedersen, Stella Trompet, Danny Tuckwell, Benoit Tyl, Andre G. Uitterlinden, Felix Vaura, Abirami Veluchamy, Peter M. Visscher, Uwe Völker, Adriaan A. Voors, Xiaosong Wang, Nicholas J. Wareham, Peter E. Weeke, Raul Weiss, Harvey D. White, Kerri L. Wiggins, Heming Xing, Jian Yang, Yifan Yang, Laura M. Yerges‐Armstrong, Bing Yu, Faiez Zannad, Faye Zhao, Regeneron Genetics Center, Jemma B. Wilk, Hilma Holm, Naveed Sattar, Steven A. Lubitz, David E. Lanfear, Svati Shah, Michael E. Dunn, Quinn S. Wells, Folkert W. Asselbergs, Aroon D. Hingorani, Marie‐Pierre Dubé, Nilesh J. Samani, Chim C. Lang, Thomas P. Cappola, Patrick T. Ellinor, Ramachandran S. Vasan, and J. Gustav Smith
- Subjects
Heart failure ,Cardiomyopathy ,Genetics ,Biomarkers ,Association studies ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome‐wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow‐up following heart failure diagnosis ranged from 2 to 116 months. Forty‐nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34–90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low‐frequency variants (allele frequency 0.01–0.05) at P
- Published
- 2021
- Full Text
- View/download PDF
5. High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease
- Author
-
Albina Tyker, Iazsmin Bauer Ventura, Cathryn T. Lee, Rachel Strykowski, Nicole Garcia, Robert Guzy, Renea Jablonski, Rekha Vij, Mary E. Strek, Jonathan H. Chung, and Ayodeji Adegunsoye
- Subjects
Medicine ,Science - Abstract
Abstract Rheumatoid arthritis-related interstitial lung disease (RA-ILD) is a common connective tissue disease-related ILD (CTD-ILD) associated with high morbidity and mortality. Although rheumatoid factor (RF) seropositivity is a risk factor for developing RA-ILD, the relationship between RF seropositivity, mediastinal lymph node (MLN) features, and disease progression is unknown. We aimed to determine if high-titer RF seropositivity predicted MLN features, lung function impairment, and mortality in RA-ILD. In this retrospective cohort study, we identified patients in the University of Chicago ILD registry with RA-ILD. We compared demographic characteristics, serologic data, MLN size, count and location, and pulmonary function over 36 months among patients who had high-titer RF seropositivity (≥ 60 IU/ml) and those who did not. Survival analysis was performed using Cox regression modeling. Amongst 294 patients with CTD-ILD, available chest computed tomography (CT) imaging and serologic data, we identified 70 patients with RA-ILD. Compared to RA-ILD patients with low-titer RF, RA-ILD patients with high-titer RF had lower baseline forced vital capacity (71% vs. 63%; P = 0.045), elevated anti-cyclic citrullinated peptide titer (122 vs. 201; P = 0.001), CT honeycombing (50% vs. 80%; P = 0.008), and higher number of MLN ≥ 10 mm (36% vs. 76%; P = 0.005). Lung function decline over 36 months did not differ between groups. Primary outcomes of death or lung transplant occurred more frequently in the high-titer RF group (HR 2.8; 95% CI 1.1–6.8; P = 0.028). High-titer RF seropositivity was associated with MLN enlargement, CT honeycombing, and decreased transplant-free survival. RF titer may be a useful prognostic marker for stratifying patients by pulmonary disease activity and mortality risk.
- Published
- 2021
- Full Text
- View/download PDF
6. Interstitial Lung Disease in Firefighters: An Emerging Occupational Hazard
- Author
-
Cathryn T. Lee, Iazsmin Bauer Ventura, E. Kate Phillips, Amy Leahy, Renea Jablonski, Steven Montner, Jonathan H. Chung, Rekha Vij, Ayodeji Adegunsoye, and Mary E. Strek
- Subjects
interstitial lung disease ,occupational exposure ,firefighting ,interstitial lung disease risk ,case series ,Medicine (General) ,R5-920 - Abstract
IntroductionOccupational risk factors for interstitial lung disease (ILD) are a remediable aspect of this progressive pulmonary disorder. The association between firefighting and ILD is unknown. Our objective was to assess the characteristics of firefighters with ILD from a large single-center ILD registry.MethodsThe University of Chicago ILD database was reviewed for patients with a history of firefighting. Clinical information was abstracted from the medical record. The prevalence rate ratio of firefighters in the database compared to the baseline prevalence of firefighting in the Chicago metropolitan area was calculated via the Poisson distribution.ResultsNineteen firefighters were identified; all were men. A variety of ILD subtypes were seen across the cohort, including four patients with a diagnosis of connective tissue disease. Patients had mild forced vital capacity (FVC) and moderate diffusing capacity for carbon monoxide (DLCO) decrements on presentation; three patients died and two received lung transplantation over an average follow-up time of 76 months. Firefighters were seen at a greater proportion in the ILD registry than in the general population with a prevalence rate ratio of 3.98.ConclusionsFirefighting was overrepresented in our cohort compared to the general population, suggesting that there may be a causative association between firefighting and the presence of ILD. The wide variety of ILD subtypes observed suggest that all ILD patients should be asked about their occupational history. Further investigation to identify occupational exposures and determine the benefit of remediation is needed.
- Published
- 2022
- Full Text
- View/download PDF
7. Diagnostic test interpretation and referral delay in patients with interstitial lung disease
- Author
-
David Pritchard, Ayodeji Adegunsoye, Elyse Lafond, Janelle Vu Pugashetti, Ryan DiGeronimo, Noelle Boctor, Nandini Sarma, Isabella Pan, Mary Strek, Michael Kadoch, Jonathan H. Chung, and Justin M. Oldham
- Subjects
Interstitial lung disease ,Diagnostic delay ,Idiopathic pulmonary fibrosis ,Pulmonary function test ,Computed tomography ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Diagnostic delays are common in patients with interstitial lung disease (ILD). A substantial percentage of patients experience a diagnostic delay in the primary care setting, but the factors underpinning this observation remain unclear. In this multi-center investigation, we assessed ILD reporting on diagnostic test interpretation and its association with subsequent pulmonology referral by a primary care physician (PCP). Methods A retrospective cohort analysis of patients referred to the ILD programs at UC-Davis and University of Chicago by a PCP within each institution was performed. Computed tomography (CT) of the chest and abdomen and pulmonary function test (PFT) were reviewed to identify the date ILD features were first present and determine the time from diagnostic test to pulmonology referral. The association between ILD reporting on diagnostic test interpretation and pulmonology referral was assessed, as was the association between years of diagnostic delay and changes in fibrotic features on longitudinal chest CT. Results One hundred and forty-six patients were included in the final analysis. Prior to pulmonology referral, 66% (n = 97) of patients underwent chest CT, 15% (n = 21) underwent PFT and 15% (n = 21) underwent abdominal CT. ILD features were reported on 84, 62 and 33% of chest CT, PFT and abdominal CT interpretations, respectively. ILD reporting was associated with shorter time to pulmonology referral when undergoing chest CT (1.3 vs 15.1 months, respectively; p = 0.02), but not PFT or abdominal CT. ILD reporting was associated with increased likelihood of pulmonology referral within 6 months of diagnostic test when undergoing chest CT (rate ratio 2.17, 95% CI 1.03–4.56; p = 0.04), but not PFT or abdominal CT. Each year of diagnostic delay was associated with a 1.8% increase in percent fibrosis on chest CT. Patients with documented dyspnea had shorter time to chest CT acquisition and pulmonology referral than patients with documented cough and lung crackles. Conclusions Determinants of ILD diagnostic delays in the primary care setting include underreporting of ILD features on diagnostic testing and prolonged time to pulmonology referral even when ILD is reported. Interventions to modulate these factors may reduce ILD diagnostic delays in the primary care setting.
- Published
- 2019
- Full Text
- View/download PDF
8. Duration of rheumatoid arthritis and the risk of developing interstitial lung disease
- Author
-
Michael P. Mohning, Isabelle Amigues, M. Kristen Demoruelle, Evans R. Fernández Pérez, Tristan J. Huie, Rebecca K. Keith, Amy L. Olson, Zulma X. Yunt, Jonathan H. Chung, Stephen Hobbs, Jeffrey J. Swigris, and Joshua J. Solomon
- Subjects
Medicine - Published
- 2021
- Full Text
- View/download PDF
9. HRCT evaluation of patients with interstitial lung disease: comparison of the 2018 and 2011 diagnostic guidelines
- Author
-
Steven D. Nathan, Jean Pastre, Inga Ksovreli, Scott Barnett, Christopher King, Shambhu Aryal, Kareem Ahmad, Cesar Fukuda, Vijaya Ramalingam, and Jonathan H. Chung
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Background and aims: Chest high-resolution computed tomography (HRCT) is the central diagnostic tool in discerning idiopathic pulmonary fibrosis (IPF) from other interstitial lung disease (ILDs). In 2018, new guidelines were published and the nomenclature for HRCT interpretation was changed. We sought to evaluate how clinicians’ interpretation would change based on reading HRCTs under the framework of the old versus new categorization. Materials and methods: We collated HRCTs from 50 random cases evaluated in the Inova Fairfax ILD clinic. Six ILD experts were provided the deidentified HRCTs. They were all instructed to independently provide two reads of each HRCT, based on the old and the new guidelines. Results: The kappa statistic for concordance for HRCT reads under old guidelines was 0.5, while for the new guidelines it was 0.38. Under the framework of the old guidelines, there were 22 HRCTs with unanimous consensus reads, while only 15 with the new guidelines. There were 12 HRCTs read unanimously as usual interstitial pneumonia (UIP) pattern based on both the old and the new guidelines. Ten HRCTs were read as a possible UIP pattern based on the old guidelines and were classified in nine cases as probable UIP and one indeterminate based on the new guidelines. Of the 28 inconsistent UIP HRCTs (old guidelines), 25 were read as alternative diagnosis suggested, two were read as indeterminate and one as probable UIP. Conclusion: Implementation of the new guidelines to categorize HRCTs in ILD patients appears to be associated with greater inter-interpreter variability. How or whether new guidelines improve the care and management of ILD patients remains unclear. The reviews of this paper are available via the supplemental material section.
- Published
- 2020
- Full Text
- View/download PDF
10. N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia
- Author
-
Justin M. Oldham, Leah J. Witt, Ayodeji Adegunsoye, Jonathan H. Chung, Cathryn Lee, Scully Hsu, Lena W. Chen, Aliya Husain, Steven Montner, Rekha Vij, Mary E. Strek, and Imre Noth
- Subjects
Idiopathic pulmonary fibrosis ,Interstitial lung disease ,Interstitial pneumonia with autoimmune features ,Anti-nuclear autoantibody ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Mortality is similarly high among individuals with usual interstitial pneumonia (UIP) due to idiopathic pulmonary fibrosis (IPF) and interstitial pneumonia with autoimmune features (IPAF). Circulating anti-nuclear antibodies (ANA) are commonly found in this patient population, suggesting possible aberrant immune activation. Because an environment of oxidative stress can result from immunologic activation, we hypothesized that ANA positive patients with UIP would have improved outcome when exposed to the antioxidant N-acetylcysteine (NAC) compared to ANA negative patients. Methods A single center, retrospective cohort analysis was performed. Patients with UIP due to IPF and IPAF were stratified according to ANA status to and NAC exposure. Transplant-free survival (TFS) was assessed using the Kaplan-Meier estimator and multivariable Cox regression adjusted for diagnosis, gender/age/physiology score, immunosuppressant exposure and anti-fibrotic exposure. Results Of 293 individuals with UIP due to IPF (74%) or IPAF (26%), NAC exposure was documented in 58 (19.8%). Among NAC exposed individuals, 33 (56.9%) were ANA seropositive and 25 (43.1%) were seronegative. NAC exposure was associated with improved TFS survival among ANA seropositive individuals in unadjusted analysis (plogrank = 0.02) and after multi-variable adjustment (HR 0.51, 95% CI 0.30–0.87; p = 0.01). There was no association between NAC exposure and TFS in ANA seronegative individuals (HR 1.26, 95% CI 0.69–2.32; p = 0.45). Formal interaction testing confirmed NAC*ANA interaction (p = 0.04) and sensitivity analysis demonstrated an increasing effect size associated with NAC therapy as ANA titer increased. Among patients with available genetic data, a marginally higher proportion of ANA positive patients (p = 0.08) carried the rs3750920 (TOLLIP) genotype previously shown to predict favorable outcome in NAC exposed patients. Conclusion NAC exposure is associated with improved transplant-free survival ANA positive patients with UIP. These findings support the prospective collection of ANA data in in future NAC clinical trials performed in patients with UIP.
- Published
- 2018
- Full Text
- View/download PDF
11. Autoimmune Hypothyroidism As a Predictor of Mortality in Chronic Hypersensitivity Pneumonitis
- Author
-
Ayodeji Adegunsoye, Justin M. Oldham, Aliya N. Husain, Lena Chen, Scully Hsu, Steven Montner, Jonathan H. Chung, Rekha Vij, Imre Noth, and Mary E. Strek
- Subjects
autoimmunity ,hypothyroidism ,hypersensitivity pneumonitis ,extrinsic allergic alveolitis ,pulmonary fibrosis ,Medicine (General) ,R5-920 - Abstract
BackgroundChronic hypersensitivity pneumonitis (CHP) is a fibrotic parenchymal lung disease that occurs when inhalation of environmental antigens leads to immune dysregulation. Autoimmune features have recently been identified as potentially important among patients with CHP. However, the relationship between hypothyroidism (HT) and CHP is unknown. In this study, we investigate the prevalence and impact of HT among patients with CHP.MethodsWe conducted a retrospective, case–control analysis. We identified 121 patients at the University of Chicago Interstitial Lung Disease Center with a multidisciplinary diagnosis of CHP. These patients were matched 3:1 according to age, sex, and race to 363 control subjects with asthma from 2006 to 2015. We analyzed demographics, clinical characteristics, and survival between both groups and assessed the relationship of HT with CHP. Survival analysis was performed using Cox proportional hazards modeling.ResultsPatients with CHP had higher prevalence of HT (25.6%, n = 31) compared to controls (10.7%, n = 39; OR, 2.86; 95% CI, 1.62–4.99; P
- Published
- 2017
- Full Text
- View/download PDF
12. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis
- Author
-
Ayodeji Adegunsoye, Justin M. Oldham, Evans R. Fernández Pérez, Mark Hamblin, Nina Patel, Mitchell Tener, Deepa Bhanot, Lacey Robinson, Sam Bullick, Lena Chen, Scully Hsu, Matthew Churpek, Donald Hedeker, Steven Montner, Jonathan H. Chung, Aliya N. Husain, Imre Noth, Mary E. Strek, and Rekha Vij
- Subjects
Medicine - Abstract
In chronic hypersensitivity pneumonitis (CHP), lack of improvement or declining lung function may prompt use of immunosuppressive therapy. We hypothesised that use of azathioprine or mycophenolate mofetil with prednisone reduces adverse events and lung function decline, and improves transplant-free survival. Patients with CHP were identified. Demographic features, pulmonary function tests, incidence of treatment-emergent adverse events (TEAEs) and transplant-free survival were characterised, compared and analysed between patients stratified by immunosuppressive therapy. A multicentre comparison was performed across four independent tertiary medical centres. Among 131 CHP patients at the University of Chicago medical centre (Chicago, IL, USA), 93 (71%) received immunosuppressive therapy, and had worse baseline forced vital capacity (FVC) and diffusing capacity, and increased mortality compared with those who did not. Compared to patients treated with prednisone alone, TEAEs were 54% less frequent with azathioprine therapy (p=0.04) and 66% less frequent with mycophenolate mofetil (p=0.002). FVC decline and survival were similar between treatment groups. Analyses of datasets from four external tertiary medical centres confirmed these findings. CHP patients who did not receive immunosuppressive therapy had better survival than those who did. Use of mycophenolate mofetil or azathioprine was associated with a decreased incidence of TEAEs, and no difference in lung function decline or survival when compared with prednisone alone. Early transition to mycophenolate mofetil or azathioprine may be an appropriate therapeutic approach in CHP, but more studies are needed.
- Published
- 2017
- Full Text
- View/download PDF
13. Radiomics-based texture analysis of idiopathic pulmonary fibrosis for genetic and survival predictions.
- Author
-
Jorie D. Budzikowski, Ahmed A. Rashid, Joseph J. Foy, Jonathan H. Chung, Imre Noth, and Samuel G. Armato III
- Published
- 2020
- Full Text
- View/download PDF
14. ACR Appropriateness Criteria® Routine Chest Imaging
- Author
-
Tami J. Bang, Jonathan H. Chung, Christopher M. Walker, Anupama G. Brixey, Jared D. Christensen, Saadia A. Faiz, Michael Hanak, Stephen B. Hobbs, Asha Kandathil, Brent P. Little, Rachna Madan, William H. Moore, Ilana B. Richman, Belinda Setters, Michael J. Todd, Stephen C. Yang, and Edwin F. Donnelly
- Subjects
Radiology, Nuclear Medicine and imaging - Published
- 2023
15. Upper Lobe Pulmonary Fibrosis: An Atypical Location for Pulmonary Fibrosis
- Author
-
Alexander W. Matyga, Lydia Chelala, and Jonathan H. Chung
- Subjects
Pulmonary and Respiratory Medicine - Published
- 2023
16. Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis
- Author
-
Daniel-Costin Marinescu, Ganesh Raghu, Martine Remy-Jardin, William D. Travis, Ayodeji Adegunsoye, Mary Beth Beasley, Jonathan H. Chung, Andrew Churg, Vincent Cottin, Ryoko Egashira, Evans R. Fernández Pérez, Yoshikazu Inoue, Kerri A. Johannson, Ella A. Kazerooni, Yet H. Khor, David A. Lynch, Nestor L. Müller, Jeffrey L. Myers, Andrew G. Nicholson, Sujeet Rajan, Ryoko Saito-Koyama, Lauren Troy, Simon L.F. Walsh, Athol U. Wells, Marlies S. Wijsenbeek, Joanne L. Wright, and Christopher J. Ryerson
- Subjects
Pulmonary and Respiratory Medicine ,Humans ,Lung Diseases, Interstitial ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine ,Lung ,Idiopathic Pulmonary Fibrosis ,Alveolitis, Extrinsic Allergic - Abstract
Recent clinical practice guidelines have addressed the diagnosis of idiopathic pulmonary fibrosis (IPF) and fibrotic hypersensitivity pneumonitis (fHP). These disease-specific guidelines were developed independently, without clear direction on how to apply their respective recommendations concurrently within a single patient, where discrimination between these two fibrotic interstitial lung diseases represents a frequent diagnostic challenge. The objective of this review, created by an international group of experts, was to suggest a pragmatic approach on how to apply existing guidelines to distinguish IPF and fHP. Key clinical, radiologic, and pathologic features described in previous guidelines are integrated in a set of diagnostic algorithms, which then are placed in the broader context of multidisciplinary discussion to guide the generation of a consensus diagnosis. Although these algorithms necessarily reflect some uncertainty wherever strong evidence is lacking, they provide insight into the current approach favored by experts in the field based on currently available knowledge. The authors further identify priorities for future research to clarify ongoing uncertainties in the diagnosis of fibrotic interstitial lung diseases.
- Published
- 2022
17. CPFE Supplement
- Author
-
Dylan Douglas, Layne Keating, Rachel Strykowski, Cathryn T Lee, Nicole Garcia, Kavitha Selvan, Neha Kaushik, Iazsmin Bauer Ventura, Renea Jabolonski, Rekha Vij, Jonathan H. Chung, Shashi Bellam, Mary E. Strek, and Ayodeji Adegunsoye
- Abstract
Supplemental Figures and Tables
- Published
- 2023
- Full Text
- View/download PDF
18. ACR Appropriateness Criteria® Diffuse Lung Disease
- Author
-
Jonathan H. Chung, Asha Kandathil, Expert Panel on Thoracic Imaging, Sonye K. Danoff, Tami J. Bang, Stephen B. Hobbs, Brett W. Carter, William Moore, Christopher M. Walker, Jeffrey P. Kanne, Rachna Madan, Jared D. Christensen, and Sachin D. Shah
- Subjects
medicine.medical_specialty ,Lung ,Exacerbation ,business.industry ,Interstitial lung disease ,medicine.disease ,Appropriate Use Criteria ,Appropriateness criteria ,medicine.anatomical_structure ,medicine ,Etiology ,Radiology, Nuclear Medicine and imaging ,business ,Intensive care medicine ,Grading (tumors) ,Medical literature - Abstract
Diffuse lung disease, frequently referred to as interstitial lung disease, encompasses numerous disorders affecting the lung parenchyma. The potential etiologies of diffuse lung disease are broad with several hundred established clinical syndromes and pathologies currently identified. Imaging plays a critical role in diagnosis and follow-up of many of these diseases, although multidisciplinary discussion is the current standard for diagnosis of several DLDs. This document aims to establish guidelines for evaluation of diffuse lung diseases for 1) initial imaging of suspected diffuse lung disease, 2) initial imaging of suspected acute exacerbation or acute deterioration in cases of confirmed diffuse lung disease, and 3) clinically indicated routine follow-up of confirmed diffuse lung disease without acute deterioration. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
- Published
- 2021
19. ACR Appropriateness Criteria® Nontraumatic Chest Wall Pain
- Author
-
Stephen B. Hobbs, William Moore, Tami J. Bang, Brett W. Carter, Tarek N. Hanna, Christopher M. Walker, Justin T Stowell, Expert Panel on Thoracic Imaging, Braeden D Johnson, Asha Kandathil, Rachna Madan, Jeffrey P. Kanne, Jared D. Christensen, Edwin F. Donnelly, Bruce M. Lo, Sarah Majercik, and Jonathan H. Chung
- Subjects
medicine.medical_specialty ,Costochondritis ,business.industry ,Emergency department ,medicine.disease ,Chest pain ,Chest Wall Pain ,Appropriate Use Criteria ,Ambulatory ,medicine ,Radiology, Nuclear Medicine and imaging ,medicine.symptom ,Intensive care medicine ,business ,Medical literature - Abstract
Chest pain is a common reason that patients may present for evaluation in both ambulatory and emergency department settings, and is often of musculoskeletal origin in the former. Chest wall syndrome collectively describes the various entities that can contribute to chest wall pain of musculoskeletal origin and may affect any chest wall structure. Various imaging modalities may be employed for the diagnosis of nontraumatic chest wall conditions, each with variable utility depending on the clinical scenario. We review the evidence for or against use of various imaging modalities for the diagnosis of nontraumatic chest wall pain. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
- Published
- 2021
20. CT Findings and Patterns of e-Cigarette or Vaping Product Use-Associated Lung Injury
- Author
-
Jeffrey P. Kanne, Constantine A. Raptis, Travis S. Henry, Christopher M. Walker, Peter D. Filev, Michael S Chung, Kaitlin M Marquis, Fernando Uliana Kay, Subba R. Digumarthy, Seth Kligerman, Alan M Ropp, Jonathan H. Chung, Kristen Pope, Tan-Lucien H. Mohammed, Daniel Vargas, and Jacob W. Sechrist
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,government.form_of_government ,Diffuse alveolar hemorrhage ,Lung injury ,Critical Care and Intensive Care Medicine ,medicine.disease ,Gastroenterology ,Ground-glass opacity ,03 medical and health sciences ,Pneumonia ,0302 clinical medicine ,030228 respiratory system ,Acute eosinophilic pneumonia ,Internal medicine ,Cohort ,medicine ,government ,030212 general & internal medicine ,Pulmonary hemorrhage ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Diffuse alveolar damage ,business - Abstract
Background e-Cigarette or vaping-induced lung injury (EVALI) causes a spectrum of CT lung injury patterns. Relative frequencies and associations with vaping behavior are unknown. Research Question What are the frequencies of imaging findings and CT patterns in EVALI and what is the relationship to vaping behavior? Study Design and Methods CT scans of 160 subjects with EVALI from 15 institutions were retrospectively reviewed. CT findings and patterns were defined and agreed on via consensus. The parenchymal organizing pneumonia (OP) pattern was defined as regional or diffuse ground-glass opacity (GGO) ± consolidation without centrilobular nodules (CNs). An airway-centered OP pattern was defined as diffuse CNs with little or no GGO, whereas a mixed OP pattern was a combination of the two. Other patterns included diffuse alveolar damage (DAD), acute eosinophilic-like pneumonia, and pulmonary hemorrhage. Cases were classified as atypical if they did not fit into a pattern. Imaging findings, pattern frequencies, and injury severity were correlated with substance vaped (marijuana derives [tetrahydrocannabinol] [THC] only, nicotine derivates only, and both), vaping frequency, regional geography, and state recreational THC legality. One-way analysis of variance, χ2 test, and multivariable analyses were used for statistical analysis. Results A total of 160 patients (79.4% men) with a mean age of 28.2 years (range, 15-68 years) with EVALI underwent CT scan. Seventy-seven (48.1%), 15 (9.4%), and 68 (42.5%) patients admitted to vaping THC, nicotine, or both, respectively. Common findings included diffuse or lower lobe GGO with subpleural (78.1%), lobular (59.4%), or peribronchovascular (PBV) sparing (40%). Septal thickening (50.6%), lymphadenopathy (63.1%), and CNs (36.3%) were common. PBV sparing was associated with younger age (P = .02). Of 160 subjects, 156 (97.5%) had one of six defined patterns. Parenchymal, airway-centered, and mixed OP patterns were seen in 89 (55.6%), 14 (8.8%), and 32 (20%) patients, respectively. Acute eosinophilic-like pneumonia (six of 160, 3.8%), DAD (nine of 160, 5.6%), pulmonary hemorrhage (six of 160, 3.8%), and atypical (four of 160, 2.5%) patterns were less common. Increased vaping frequency was associated with more severe injury (P = .008). Multivariable analysis showed a negative association between vaping for > 6 months and DAD pattern (P = .03). Two subjects (1.25%) with DAD pattern died. There was no relation between pattern and injury severity, geographic location, and state legality of recreational use of THC. Interpretation EVALI typically causes an OP pattern but exists on a spectrum of acute lung injury. Vaping habits do not correlate with CT patterns except for negative correlation between vaping > 6 months and DAD pattern. PBV sparing, not previously described in acute lung injury, is a common finding.
- Published
- 2021
21. The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation
- Author
-
Fayez Kheir, Barry S. Shea, Frederick L Rudell, Christopher S. King, Pauline Bianchi, Anja C. Roden, Krishna Thavarajah, Ashok Muniappan, Jonathan H. Chung, Zeenat Safdar, David J. Lederer, Luca Paoletti, Matthew G. Hartwig, Sally Suliman, Brett Ley, Jeffrey L. Myers, Joshua J. Mooney, Lida P. Hariri, Sonye K. Danoff, David A. Lynch, Diana Gomez Manjarres, Rishi Raj, and Maryl Kreider
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Biopsy ,Pulmonary Fibrosis ,Lung biopsy ,behavioral disciplines and activities ,03 medical and health sciences ,Idiopathic pulmonary fibrosis ,0302 clinical medicine ,Bronchoscopy ,Pulmonary fibrosis ,Humans ,Medicine ,In patient ,030212 general & internal medicine ,Microscopic pathology ,Lung ,Pulmonologists ,business.industry ,Interstitial lung disease ,respiratory system ,medicine.disease ,Idiopathic Pulmonary Fibrosis ,respiratory tract diseases ,body regions ,030228 respiratory system ,Tissue diagnosis ,Radiology ,Lung Diseases, Interstitial ,business - Abstract
Diagnosis of interstitial lung disease (ILD) requires a multidisciplinary discussion approach that includes clinicians, radiologists, and pathologists. Surgical lung biopsy (SLB) is currently the recommended standard in obtaining pathologic specimens for patients with ILD requiring a tissue diagnosis. The increased diagnostic confidence and accuracy provided by microscopic pathology assessment of SLB specimens must be balanced with the associated risks in patients with ILD. This document was developed by the SLB Working Group of the Pulmonary Fibrosis Foundation, composed of a multidisciplinary group of ILD physicians, including pulmonologists, radiologists, pathologists, and thoracic surgeons. In this document, we present an up-to-date literature review of the indications, contraindications, risks, and alternatives to SLB in the diagnosis of fibrotic ILD; outline an integrated approach to the decision-making around SLB in the diagnosis of fibrotic ILD; and provide practical information to maximize the yield and safety of SLB.
- Published
- 2021
22. Updated Imaging Classification of Hypersensitivity Pneumonitis
- Author
-
Lydia Chelala, Ayodeji Adegunsoye, Brittany A. Cody, Aliya N. Husain, and Jonathan H. Chung
- Subjects
Diagnostic Imaging ,Humans ,Radiology, Nuclear Medicine and imaging ,General Medicine ,Lung Diseases, Interstitial ,Lung ,Alveolitis, Extrinsic Allergic - Abstract
Hypersensitivity pneumonia (HP) refers to a heterogeneous group of interstitial lung diseases resulting from a non-IgE immune-mediated reaction to inhaled pathogens in susceptible and sensitized hosts. Environmental and genetic factors are important substrates of disease pathogenesis. A recurrent or ongoing airborne exposure results in activation of humoral and cellular immune responses. This article discusses key clinical, radiologic, and histopathologic features of HP and reviews current recommendations.
- Published
- 2022
23. Percutaneous ultrasound gastrostomy (PUG): first prospective clinical trial
- Author
-
Daniele Wiseman, Derek W. Cool, Jonathan H. Chung, Amol Mujoomdar, Fabio Accorsi, and Stewart Kribs
- Subjects
Adult ,Male ,medicine.medical_specialty ,Percutaneous ,Urology ,Sedation ,medicine.medical_treatment ,Investigational device exemption ,030218 nuclear medicine & medical imaging ,Gastropexy ,03 medical and health sciences ,0302 clinical medicine ,Interventional Radiology ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Percutaneous ultrasound gastrostomy ,Adverse effect ,Ultrasonography ,Aged ,Retrospective Studies ,Gastrostomy ,Aged, 80 and over ,Radiological and Ultrasound Technology ,business.industry ,Gastroenterology ,Retrospective cohort study ,Middle Aged ,Surgery ,Clinical trial ,Treatment Outcome ,Female ,030211 gastroenterology & hepatology ,medicine.symptom ,business - Abstract
Graphical abstarct Purpose To report the results of the first-in-human trial evaluating the safety and efficacy of the percutaneous ultrasound gastrostomy (PUG) technique. Methods A prospective, industry-sponsored single-arm clinical trial of PUG insertion was performed in 25 adult patients under investigational device exemption (mean age 64 ± 15 years, 92% men, 80% inpatients, mean BMI 24.5 ± 2.7 kg/m2). A propensity score-matched retrospective cohort of 25 patients who received percutaneous radiologic gastrostomy (PRG) was generated as an institutional control (mean age 66 ± 14 years, 92% men, 80% inpatients, mean BMI 24.0 ± 2.7 kg/m2). Primary outcomes included successful insertion and 30-day procedure-related adverse events (AE’s). Secondary outcomes included procedural duration, sedation requirements, and hospital length of stay. Results All PUG procedures were successful, including 3/25 [12%] performed bedside within the ICU. There was no significant difference between PUG and PRG in rates of mild AE’s (3/25 [12%] for PUG and 7/25 [28%] for PRG, p = 0.16) or moderate AE’s (1/25 [4%] for PUG and 0/25 for PRG, p = 0.31). There were no severe AE’s or 30-day procedure-related mortality in either group. Procedural room time was longer for PUG (56.5 ± 14.1 min) than PRG (39.3 ± 15.0 min, p p = 0.70). Conclusion PUG appears effective with a safety profile similar to PRG. Bedside point-of-care gastrostomy tube insertion using the PUG technique shows promise. Trial Registration Number: ClinicalTrials.gov ID NCT03575754. Graphical abstract
- Published
- 2021
24. Vessel-related structures predict UIP pathology in those with a non-IPF pattern on CT
- Author
-
Aliya N. Husain, Rekha Vij, Justin M. Oldham, Mary E. Strek, Steven M. Montner, Ronald A. Karwoski, Ayodeji Adegunsoye, Jonathan H. Chung, and Brian J. Bartholmai
- Subjects
Univariate analysis ,medicine.medical_specialty ,Pathology ,Lung ,business.industry ,Interstitial lung disease ,General Medicine ,Lung biopsy ,respiratory system ,medicine.disease ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Usual interstitial pneumonia ,030220 oncology & carcinogenesis ,medicine ,Radiology, Nuclear Medicine and imaging ,Honeycombing ,Radiology ,business ,Pathological ,Neuroradiology - Abstract
To determine if a quantitative imaging variable (vessel-related structures [VRS]) could identify subjects with a non-IPF diagnosis CT pattern who were highly likely to have UIP histologically. Subjects with a multidisciplinary diagnosis of interstitial lung disease including surgical lung biopsy and chest CT within 1 year of each other were included in the study. Non-contrast CT scans were analyzed using the Computer-Aided Lung Informatics for Pathology Evaluation and Rating (CALIPER) program, which quantifies the amount of various abnormal CT patterns on chest CT. Quantitative data were analyzed relative to pathological diagnosis as well as the qualitative CT pattern. CALIPER-derived volumes of reticulation (p = 0.012), honeycombing (p = 0.017), and VRS (p < 0.001) were associated with a UIP pattern on pathology on univariate analysis but only VRS was associated with a UIP pathology on multivariable analysis (p = 0.013). Using a VRS cut-off of 173 cm3, the sensitivity and specificity for pathological UIP were similar to those for standard qualitative CT assessment (55.9% and 80.4% compared to 60.6% and 80.4%, respectively). VRS differentiated pathological UIP cases in those with a non-IPF diagnosis CT category (p < 0.001) but not in other qualitative CT patterns (typical UIP, probable UIP, and indeterminate for UIP). The rate of pathological UIP in those with VRS greater than 173 cm3 (84.2%) was nearly identical to those who had a qualitative CT pattern of probable UIP (88.9%). VRS may be an adjunct to CT in predicting pathology in patients with interstitial lung disease. • Volume of vessel-related structures (VRS) was associated with usual interstitial pneumonia (UIP) on pathology. • This differentiation arose from those with CT scans with a non-IPF diagnosis imaging pattern. • Higher VRS has similar diagnostic ramifications for UIP as probable UIP, transitively suggesting in patients with high VRS, pathology may be obviated.
- Published
- 2021
25. A Case for Academic Teleradiology
- Author
-
Jeffrey P. Kanne and Jonathan H. Chung
- Subjects
Teleradiology ,Humans ,Radiology, Nuclear Medicine and imaging ,Radiology - Published
- 2022
26. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
- Author
-
Pedro Blecua Carrillo Albornoz, Timothy A. Chan, Rajarsi Mandal, Qing Chang, Vladimir Makarov, Raghvendra M. Srivastava, Tanaya A. Purohit, Besnik Qeriqi, Simon N. Powell, Britta Weigelt, Elisa de Stanchina, Jeremy Setton, Jonathan H. Chung, Luc G. T. Morris, Robert M. Samstein, Ken-Wing Lee, Xin Pei, Rachna Shah, Lior Z. Braunstein, Xiaoxiao Ma, Sviatoslav M. Kendall, Douglas R. Hoen, Jorge S. Reis-Filho, Nadeem Riaz, Wei Wu, Diana Mandelker, Chirag Krishna, and Fengshen Kuo
- Subjects
Cancer Research ,Tumor microenvironment ,Innate immune system ,endocrine system diseases ,T cell ,medicine.medical_treatment ,Immunotherapy ,Dendritic cell ,Biology ,Immune checkpoint ,medicine.anatomical_structure ,Oncology ,medicine ,Cancer research ,skin and connective tissue diseases ,Gene ,Checkpoint Blockade Immunotherapy - Abstract
Immune checkpoint blockade (ICB) has improved outcomes for patients with advanced cancer, but the determinants of response remain poorly understood. Here we report differential effects of mutations in the homologous recombination genes BRCA1 and BRCA2 on response to ICB in mouse and human tumors, and further show that truncating mutations in BRCA2 are associated with superior response compared to those in BRCA1. Mutations in BRCA1 and BRCA2 result in distinct mutational landscapes and differentially modulate the tumor-immune microenvironment, with gene expression programs related to both adaptive and innate immunity enriched in BRCA2-deficient tumors. Single-cell RNA sequencing further revealed distinct T cell, natural killer, macrophage, and dendritic cell populations enriched in BRCA2-deficient tumors. Taken together, our findings reveal the divergent effects of BRCA1 and BRCA2-deficiency on ICB outcome, and have significant implications for elucidating the genetic and microenvironmental determinants of response to immunotherapy.
- Published
- 2020
27. ACR Appropriateness Criteria® Blunt Chest Trauma-Suspected Cardiac Injury
- Author
-
Diana Litmanovich, Brian B. Ghoshhajra, Seth Kligerman, Betty C. Tong, Samuel Wann, Mushabbar A Syed, Jadranka Stojanovska, Todd C. Villines, Joe Y. Hsu, Garth M. Beache, Thoracic Imaging, Andrew M. Davis, Christopher M. Walker, Stephen J. Wolf, Lynne M. Hurwitz Koweek, Patrick M. Colletti, Mark F. Berry, Suhny Abbara, Faisal Khosa, Jonathan H. Chung, Christopher D. Maroules, Jeffrey P. Kanne, Nandini M. Meyersohn, and Gregory A Kicska
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Radiography ,Myocardial contusion ,medicine.disease ,Appropriate Use Criteria ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Blunt ,030220 oncology & carcinogenesis ,Angiography ,Concussion ,Commotio cordis ,medicine ,Radiology, Nuclear Medicine and imaging ,Radiology ,business ,Medical literature - Abstract
Blunt cardiac injuries range from myocardial concussion (commotio cordis) leading to fatal ventricular arrhythmias to myocardial contusion, cardiac chamber rupture, septal rupture, pericardial rupture, and valvular injuries. Blunt injuries account for one-fourth of the traumatic deaths in the United States. Chest radiography, transthoracic echocardiography, CT chest with and without contrast, and CT angiography are usually appropriate as the initial examination in patients with suspected blunt cardiac injury who are both hemodynamically stable and unstable. Transesophageal echocardiography and CT heart may be appropriate as examination in patients with suspected blunt cardiac injuries. This publication of blunt chest trauma-suspected cardiac injuries summarizes the literature and makes recommendations for imaging based on the available data and expert opinion. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
- Published
- 2020
28. Duration of rheumatoid arthritis and the risk of developing interstitial lung disease
- Author
-
Michael P. Mohning, Isabelle Amigues, Joshua J. Solomon, Rebecca K. Keith, M. Kristen Demoruelle, Zulma X. Yunt, Evans R. Fernández Pérez, Jeffrey J. Swigris, Jonathan H. Chung, Amy L. Olson, Tristan J. Huie, and Stephen B. Hobbs
- Subjects
musculoskeletal diseases ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,MEDLINE ,lcsh:Medicine ,behavioral disciplines and activities ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,Internal medicine ,Medicine ,In patient ,030212 general & internal medicine ,business.industry ,Original Research Letters ,lcsh:R ,Interstitial lung disease ,respiratory system ,medicine.disease ,respiratory tract diseases ,body regions ,030228 respiratory system ,Duration (music) ,Rheumatoid arthritis ,business - Abstract
Rheumatoid arthritis is an autoimmune disease that classically presents as a symmetrical inflammatory polyarthritis. Extra-articular manifestations are prevalent, with the lungs being the most common site [1], and interstitial lung disease (ILD) being the most severe form of pulmonary involvement. In some studies, the median survival of patients with rheumatoid arthritis and a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) is around 3 years (similar to that in idiopathic pulmonary fibrosis (IPF) [2, 3]); however, in other studies, median survival is >7 years [4, 5]. When present, ILD accounts for 10–20% of all deaths in rheumatoid arthritis [6]., Age of ILD onset is similar in patients with RA-UIP and RA-NSIP but duration of RA before ILD onset differs https://bit.ly/3lgjfDJ
- Published
- 2020
29. Diffuse Pulmonary Ossification on High-Resolution Computed Tomography in Idiopathic Pulmonary Fibrosis, Systemic Sclerosis-Related Interstitial Lung Disease, and Chronic Hypersensitivity Pneumonitis: A Comparative Study
- Author
-
Christian W. Cox, Jonathan H. Chung, Jay H. Ryu, Lara Walkoff, and Anuj S. Dixit
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,High-resolution computed tomography ,Adolescent ,Scleroderma ,030218 nuclear medicine & medical imaging ,Young Adult ,03 medical and health sciences ,Idiopathic pulmonary fibrosis ,0302 clinical medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Honeycombing ,Young adult ,Lung ,Aged ,Aged, 80 and over ,Scleroderma, Systemic ,medicine.diagnostic_test ,business.industry ,Ossification ,Ossification, Heterotopic ,Interstitial lung disease ,Middle Aged ,respiratory system ,medicine.disease ,Idiopathic Pulmonary Fibrosis ,respiratory tract diseases ,Chronic Disease ,Female ,medicine.symptom ,Lung Diseases, Interstitial ,Tomography, X-Ray Computed ,business ,030217 neurology & neurosurgery ,Hypersensitivity pneumonitis - Abstract
Objective The aim of the study was to compare the prevalence of diffuse pulmonary ossification (DPO) in idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc)-related interstitial lung disease (ILD), and chronic hypersensitivity pneumonitis (HP). Methods High-resolution computed tomography (HRCT) from 71 IPF, 67 SSc-ILD, and 75 HP cases were independently evaluated by 2 thoracic radiologists blinded to patient data. Studies were assessed for the presence of DPO, HRCT scanning pattern, stigmata of granulomatous infection, and honeycombing. Results The prevalence of DPO was significantly higher in cases of IPF and SSc compared with HP, although there was no significant difference in prevalence between the IPF and SSc groups, even when accounting for the presence of prior granulomatous infection. Interobserver agreement for the presence of DPO was substantial. Conclusions Although prevalence DPO on HRCT varies between some forms of ILD, the use of DPO to influence characterization of ILD should be considered with caution.
- Published
- 2020
30. Multilevel Body Composition Analysis on Chest Computed Tomography Predicts Hospital Length of Stay and Complications After Lobectomy for Lung Cancer
- Author
-
Florian J. Fintelmann, Mark K. Ferguson, Cylen Javidan, Ashok Muniappan, Bryan F. Meyers, Christopher P. Bridge, Fabian M. Troschel, Jan Peter Marquardt, Darren S. Bryan, Till D. Best, Sarah F Mercaldo, Maria M Wrobel, Henning A. Gaissert, Sanjeev Bhalla, and Jonathan H. Chung
- Subjects
medicine.medical_specialty ,Lung Neoplasms ,Length of hospitalization ,Adipose tissue ,Computed tomography ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,medicine ,Humans ,Sarcopenic obesity ,Respiratory system ,Pneumonectomy ,Lung cancer ,Aged ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Odds ratio ,Length of Stay ,medicine.disease ,Hospitals ,Surgery ,030220 oncology & carcinogenesis ,Body Composition ,030211 gastroenterology & hepatology ,Tomography, X-Ray Computed ,business ,Body mass index - Abstract
Objective To investigate the impact of thoracic body composition on outcomes after lobectomy for lung cancer. Summary and background data Preoperative identification of patients at risk for adverse outcomes permits treatment modification. The impact of body composition on lung resection outcomes has not been investigated in a multicenter setting. Methods A total of 958 consecutive patients undergoing lobectomy for lung cancer at 3 centers from 2014 to 2017 were retrospectively analyzed. Muscle and adipose tissue cross-sectional area at the fifth, eighth, and tenth thoracic vertebral body was quantified. Prospectively collected outcomes from a national database were abstracted to characterize the association between sums of muscle and adipose tissue and hospital length of stay (LOS), number of any postoperative complications, and number of respiratory postoperative complications using multivariate regression. A priori determined covariates were forced expiratory volume in 1 second and diffusion capacity of the lungs for carbon monoxide predicted, age, sex, body mass index, race, surgical approach, smoking status, Zubrod and American Society of Anesthesiologists scores. Results Mean patient age was 67 years, body mass index 27.4 kg/m and 65% had stage I disease. Sixty-three percent underwent minimally invasive lobectomy. Median LOS was 4 days and 34% of patients experienced complications. Muscle (using 30 cm increments) was an independent predictor of LOS (adjusted coefficient 0.972; P = 0.002), any postoperative complications (odds ratio 0.897; P = 0.007) and postoperative respiratory complications (odds ratio 0.860; P = 0.010). Sarcopenic obesity was also associated with LOS and adverse outcomes. Conclusions Body composition on preoperative chest computed tomography is an independent predictor of LOS and postoperative complications after lobectomy for lung cancer.
- Published
- 2020
31. ACR Appropriateness Criteria® Thoracic Outlet Syndrome
- Author
-
Omar Zurkiya, Suvranu Ganguli, Sanjeeva P. Kalva, Jonathan H. Chung, Lubdha M. Shah, Bill S. Majdalany, Julie Bykowski, Brett W. Carter, Ankur Chandra, Jeremy D. Collins, Andrew J. Gunn, A. Tuba Kendi, Minhajuddin S. Khaja, David S. Liebeskind, Fabien Maldonado, Piotr Obara, Patrick D. Sutphin, Betty C. Tong, Kanupriya Vijay, Amanda S. Corey, Jeffrey P. Kanne, and Karin E. Dill
- Subjects
Thoracic outlet ,medicine.medical_specialty ,business.industry ,Paget–Schroetter disease ,medicine.disease ,Appropriate Use Criteria ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,medicine.artery ,medicine ,Radiology, Nuclear Medicine and imaging ,business ,Intensive care medicine ,Brachial plexus ,Subclavian vein ,Subclavian artery ,Thoracic outlet syndrome ,Medical literature - Abstract
Thoracic outlet syndrome (TOS) is the clinical entity that occurs with compression of the brachial plexus, subclavian artery, and/or subclavian vein at the superior thoracic outlet. Compression of each of these structures results in characteristic symptoms divided into three variants: neurogenic TOS, venous TOS, and arterial TOS, each arising from the specific structure that is compressed. The constellation of symptoms in each patient may vary, and patients may have more than one symptom simultaneously. Understanding the various anatomic spaces, causes of narrowing, and resulting neurovascular changes is important in choosing and interpreting radiological imaging performed to help diagnose TOS and plan for intervention. This publication has separated imaging appropriateness based on neurogenic, venous, or arterial symptoms, acknowledging that some patients may present with combined symptoms that may require more than one study to fully resolve. Additionally, in the postoperative setting, new symptoms may arise altering the need for specific imaging as compared to preoperative evaluation. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
- Published
- 2020
32. ACR Appropriateness Criteria® Occupational Lung Diseases
- Author
-
Christopher M. Walker, Patricia M. de Groot, Stephen B. Hobbs, Christian W. Cox, Betty C. Tong, Expert Panel on Thoracic Imaging, Brett W. Carter, Jonathan H. Chung, Barbara L. McComb, Fabien Maldonado, Geoffrey B. Johnson, Jeanne B. Ackman, Jeffrey P. Kanne, and Mark F. Berry
- Subjects
medicine.medical_specialty ,business.industry ,Pneumoconiosis ,Interstitial lung disease ,Ordering Physician ,Airway obstruction ,medicine.disease ,Appropriate Use Criteria ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Medical imaging ,medicine ,Radiology, Nuclear Medicine and imaging ,Occupational lung disease ,Intensive care medicine ,business ,Medical literature - Abstract
Ordering the appropriate diagnostic imaging for occupational lung disease requires a firm understanding of the relationship between occupational exposure and expected lower respiratory track manifestation. Where particular inorganic dust exposures typically lead to nodular and interstitial lung disease, other occupational exposures may lead to isolated small airway obstruction. Certain workplace exposures, like asbestos, increase the risk of malignancy, but also produce pulmonary findings that mimic malignancy. This publication aims to delineate the common and special considerations associated with occupational lung disease to assist the ordering physician in selecting the most appropriate imaging study, while still stressing the importance of a multidisciplinary approach. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
- Published
- 2020
33. Total Synthesis and Antitrypanosomal Activity of Janadolide and Simplified Analogues
- Author
-
Kieran Geraghty, Jonathan H. Chung, Richard J. Payne, Arthur H Tang, Leo Corcilius, and Marcel Kaiser
- Subjects
Trypanosoma brucei rhodesiense ,Stereochemistry ,Trypanosoma cruzi ,Antiprotozoal Agents ,010402 general chemistry ,Peptides, Cyclic ,01 natural sciences ,Biochemistry ,Janadolide ,chemistry.chemical_compound ,Polyketide ,Parasitic Sensitivity Tests ,Suzuki reaction ,parasitic diseases ,Physical and Theoretical Chemistry ,Natural product ,Molecular Structure ,biology ,010405 organic chemistry ,Organic Chemistry ,Enantioselective synthesis ,Total synthesis ,biology.organism_classification ,0104 chemical sciences ,chemistry - Abstract
Janadolide is a cyclic depsipeptide natural product isolated from the marine cyanobacterium Okeania sp. Herein, we describe the total synthesis of janadolide, along with eight simplified analogues, via an efficient solid-phase strategy. Crucial to the synthesis of the natural product was the construction of a key polyketide fragment via an enantioselective (-)-B-chlorodiisopinocampheylborane-mediated reduction and a B-alkyl Suzuki reaction. Janadolide and the simplified analogues exhibited antitrypanosomal activity against pathogenic Trypanosoma brucei rhodesiense and Trypanosoma cruzi parasites.
- Published
- 2020
34. Sarcoidosis: A Diagnosis of Exclusion
- Author
-
Lucas Meek, Jonathan H. Chung, Stephen B. Hobbs, Christopher M. Walker, Kristen Pope, and Gregory M. Lee
- Subjects
medicine.medical_specialty ,business.industry ,Pneumoconiosis ,General Medicine ,medicine.disease ,Dermatology ,Diagnosis of exclusion ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Granuloma ,Pulmonary fibrosis ,Medicine ,Radiology, Nuclear Medicine and imaging ,Sarcoidosis ,business - Abstract
OBJECTIVE. This article will review the typical and atypical imaging features of sarcoidosis, identify entities that may be mistaken for sarcoidosis, and discuss patterns and clinical scenarios tha...
- Published
- 2020
35. A Fully Automated Deep Learning Pipeline for Multi–Vertebral Level Quantification and Characterization of Muscle and Adipose Tissue on Chest CT Scans
- Author
-
Christopher P. Bridge, Till D. Best, Maria M. Wrobel, J. Peter Marquardt, Kirti Magudia, Cylen Javidan, Jonathan H. Chung, Jayashree Kalpathy-Cramer, Katherine P. Andriole, and Florian J. Fintelmann
- Subjects
Radiological and Ultrasound Technology ,Artificial Intelligence ,Radiology, Nuclear Medicine and imaging ,AI in Brief - Abstract
Body composition on chest CT scans encompasses a set of important imaging biomarkers. This study developed and validated a fully automated analysis pipeline for multi–vertebral level assessment of muscle and adipose tissue on routine chest CT scans. This study retrospectively trained two convolutional neural networks on 629 chest CT scans from 629 patients (55% women; mean age, 67 years ± 10 [standard deviation]) obtained between 2014 and 2017 prior to lobectomy for primary lung cancer at three institutions. A slice-selection network was developed to identify an axial image at the level of the fifth, eighth, and 10th thoracic vertebral bodies. A segmentation network (U-Net) was trained to segment muscle and adipose tissue on an axial image. Radiologist-guided manual-level selection and segmentation generated ground truth. The authors then assessed the predictive performance of their approach for cross-sectional area (CSA) (in centimeters squared) and attenuation (in Hounsfield units) on an independent test set. For the pipeline, median absolute error and intraclass correlation coefficients for both tissues were 3.6% (interquartile range, 1.3%–7.0%) and 0.959–0.998 for the CSA and 1.0 HU (interquartile range, 0.0–2.0 HU) and 0.95–0.99 for median attenuation. This study demonstrates accurate and reliable fully automated multi–vertebral level quantification and characterization of muscle and adipose tissue on routine chest CT scans. Keywords: Skeletal Muscle, Adipose Tissue, CT, Chest, Body Composition Analysis, Convolutional Neural Network (CNN), Supervised Learning Supplemental material is available for this article. © RSNA, 2022
- Published
- 2022
36. Performance of the right ventricular outflow tract/aortic diameter as a novel predictor of risk in patients with acute pulmonary embolism
- Author
-
Margaret Lee, Alexandru Marginean, Jonathan Paul, Anthony Serritella, Atman P. Shah, Sandeep Nathan, Andrew Putnam, Janet Friant, Stephanie A. Besser, Taishi Hirai, John E.A. Blair, and Jonathan H. Chung
- Subjects
Male ,Cardiac output ,medicine.medical_specialty ,Computed Tomography Angiography ,Heart Ventricles ,Ventricular Dysfunction, Right ,Hemodynamics ,030204 cardiovascular system & hematology ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine.artery ,Odds Ratio ,medicine ,Humans ,Ventricular outflow tract ,In patient ,030212 general & internal medicine ,Cardiac Output ,Aorta ,Pulmonary Valve ,High risk patients ,business.industry ,Patient Selection ,Organ Size ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,United States ,Pulmonary embolism ,Echocardiography ,Pulmonary artery ,Cardiology ,Female ,Aortic diameter ,Pulmonary Embolism ,Cardiology and Cardiovascular Medicine ,business - Abstract
Right ventricular (RV) enlargement, determined via the ratio of the right to left ventricular diameters (RV/LV) by CT imaging is used to classify the severity of acute pulmonary embolism (PE) and impacts treatment decisions. The RV/LV ratio may be an unreliable marker of RV dysfunction, due in part to the complex RV geometry. This study compared the RV/LV ratio to a novel metric, the ratio of the right ventricular to aortic outflow tract diameters (RVOT/Ao) in patients with acute PE treated with catheter-directed therapies (CDT). RVOT/Ao and RV/LV ratios were measured on CT images from 103 patients who received CDT for acute submassive or massive PE and were compared to RV dysfunction severity determined by transthoracic echocardiography. Ratios and biomarkers on admission were assessed for correlation with invasively-measured hemodynamics [right atrial (RA) pressure, mean pulmonary artery (PA) pressure, cardiac output (CO)]. RVOT/Ao but not RV/LV ratios were increased in patients with moderate or severe RV dysfunction compared to those without RV dysfunction (p 0.05). Neither ratio showed significant correlation with RA (r = 0.09 vs 0.055, p 0.05), mean PA pressure (r = 0.167 vs 0.146, p 0.05), or CO (r = 0.021 vs - 0.183, p 0.05). proBNP correlated with mean PA pressure (r = 0.377, p 0.05). The RVOT/Ao ratio may be better at assessing RV dysfunction than the RV/LV ratio in patients presenting with acute PE. Although currently accepted protocols rely on the RV/LV ratio in determining when CDT are of benefit, the RVOT/Ao ratio may be a more useful tool in identifying high risk patients.
- Published
- 2019
37. High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease
- Author
-
Rachel Strykowski, Robert D. Guzy, Cathryn Lee, R. Jablonski, Rekha Vij, Iazsmin Bauer Ventura, Ayodeji Adegunsoye, Nicole Garcia, Mary E. Strek, Jonathan H. Chung, and Albina Tyker
- Subjects
Adult ,Male ,Vital capacity ,medicine.medical_specialty ,Time Factors ,Mediastinal lymphadenopathy ,Science ,Lymphadenopathy ,Risk Assessment ,Gastroenterology ,Article ,Pulmonary function testing ,Arthritis, Rheumatoid ,Predictive Value of Tests ,Rheumatoid Factor ,Risk Factors ,Internal medicine ,Mediastinal Diseases ,Humans ,Medicine ,Rheumatoid factor ,Registries ,Honeycombing ,Rheumatoid arthritis ,Risk factor ,Aged ,Retrospective Studies ,Respiratory tract diseases ,Multidisciplinary ,business.industry ,Interstitial lung disease ,Middle Aged ,respiratory system ,Prognosis ,medicine.disease ,respiratory tract diseases ,body regions ,Disease Progression ,Female ,Lung Diseases, Interstitial ,business ,Biomarkers - Abstract
Rheumatoid arthritis-related interstitial lung disease (RA-ILD) is a common connective tissue disease-related ILD (CTD-ILD) associated with high morbidity and mortality. Although rheumatoid factor (RF) seropositivity is a risk factor for developing RA-ILD, the relationship between RF seropositivity, mediastinal lymph node (MLN) features, and disease progression is unknown. We aimed to determine if high-titer RF seropositivity predicted MLN features, lung function impairment, and mortality in RA-ILD. In this retrospective cohort study, we identified patients in the University of Chicago ILD registry with RA-ILD. We compared demographic characteristics, serologic data, MLN size, count and location, and pulmonary function over 36 months among patients who had high-titer RF seropositivity (≥ 60 IU/ml) and those who did not. Survival analysis was performed using Cox regression modeling. Amongst 294 patients with CTD-ILD, available chest computed tomography (CT) imaging and serologic data, we identified 70 patients with RA-ILD. Compared to RA-ILD patients with low-titer RF, RA-ILD patients with high-titer RF had lower baseline forced vital capacity (71% vs. 63%; P = 0.045), elevated anti-cyclic citrullinated peptide titer (122 vs. 201; P = 0.001), CT honeycombing (50% vs. 80%; P = 0.008), and higher number of MLN ≥ 10 mm (36% vs. 76%; P = 0.005). Lung function decline over 36 months did not differ between groups. Primary outcomes of death or lung transplant occurred more frequently in the high-titer RF group (HR 2.8; 95% CI 1.1–6.8; P = 0.028). High-titer RF seropositivity was associated with MLN enlargement, CT honeycombing, and decreased transplant-free survival. RF titer may be a useful prognostic marker for stratifying patients by pulmonary disease activity and mortality risk.
- Published
- 2021
38. Mortality Risk from COVID-19 among Unvaccinated Subjects with Autoimmune Phenotypes of Interstitial Lung Disease
- Author
-
Mary E. Strek, Cathryn Lee, R. Jablonski, Maria Poonawalla, Jonathan H. Chung, Iazsmin Bauer Ventura, Ayodeji Adegunsoye, Rekha Vij, Nicole Garcia, Rachel Strykowski, Robert D. Guzy, and Albina Tyker
- Subjects
body regions ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Immunology ,Interstitial lung disease ,medicine ,respiratory system ,medicine.disease ,business ,behavioral disciplines and activities ,Phenotype ,respiratory tract diseases - Abstract
Background: The impact of the SARS-CoV-2 virus on patients with interstitial lung disease (ILD) remains poorly understood. As patients with ILD often have severe underlying lung parenchymal involvement, and immunosuppressive therapy is common in this population, they are presumed to be at high risk for severe COVID-19 pneumonitis. We investigated differences between those with ILD who tested positive for the SARS-CoV-2 virus compared to those with ILD who did not, and explored the relationship with use of immunosuppressive therapy.Methods: In this retrospective cohort study, we identified patients evaluated at the University of Chicago in 2020 with a multidisciplinary diagnosis of ILD, and stratified by detection of the SARS-CoV-2 virus presence or absence on PCR. Demographic data, laboratory values, and pulmonary function testing values were obtained at time of ILD diagnosis. Immunosuppressive therapies received since ILD diagnosis were assessed, as was mortality. Variable comparisons were determined by two-sided t-tests, or chi-square tests as appropriate, and logistic regression models were fitted to assess the odds of death from COVID-19 using generalized linear models with maximum-likelihood estimation.Results: Of the 309 individuals with ILD in our cohort, 6.8% (n=21) tested positive for SARS-CoV-2. Those that were SARS-CoV-2 positive were younger (57 yrs vs 66 yrs; P=0.002), had baseline higher TLC (81% vs 73%, P=0.045), similar FVC (71% vs. 67%, P=0.37), and similar DLCO (71% vs. 62%, P=0.10) at baseline. Among patients with ILD and COVID-19, 67% had received immunosuppressive therapies compared to 74% of those with ILD without COVID-19. Those with ILD and COVID-19 were also more likely to have had a diagnosis of autoimmune related-ILD (CTD-ILD or IPAF) (62% vs 38%, P=0.029), and were more frequently hypoxemic (SpO2 ≤ 92%; 4% vs 19%; P=0.012) at ILD diagnosis than those without COVID-19. The majority of patients (62%) with COVID-19 had received lymphocyte-depleting immunosuppressive therapy prior to infection. Overall, the mortality hazard was highest amongst unvaccinated subjects with autoimmune related-ILD who had COVID-19 (OR=9.6, 95%CI=1.7-54.0; P=0.01).Conclusion: SARS-CoV-2 is prevalent in ILD, and may put those who are younger, with autoimmune ILD, and on immunosuppressive therapy at higher risk. Larger studies are needed to fully explore the relationship between ILD and immunosuppressive therapy in COVID-19.
- Published
- 2021
39. Computed Tomography Findings Suggestive of Connective Tissue Disease in the Setting of Usual Interstitial Pneumonia
- Author
-
Steven D. Nathan, Steven M. Montner, Jonathan H. Chung, Scott D. Barnett, Brenna Cannon, and Prahasit Thirkateh
- Subjects
Male ,medicine.medical_specialty ,Radiography ,behavioral disciplines and activities ,environment and public health ,Gastroenterology ,Sensitivity and Specificity ,Cohort Studies ,Idiopathic pulmonary fibrosis ,Usual interstitial pneumonia ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Honeycombing ,Connective Tissue Diseases ,Lung ,Survival analysis ,Aged ,business.industry ,Interstitial lung disease ,Reproducibility of Results ,respiratory system ,Middle Aged ,medicine.disease ,Connective tissue disease ,Idiopathic Pulmonary Fibrosis ,respiratory tract diseases ,body regions ,Cohort ,Female ,business ,Tomography, X-Ray Computed - Abstract
PURPOSE A usual interstitial pneumonia (UIP) pattern is common in idiopathic pulmonary fibrosis (IPF) and connective tissue disease-related interstitial lung disease (CTD-ILD). The purpose of the study was to validate imaging findings differentiating CTD-ILD from IPF in UIP. METHODS Patients with a multidisciplinary diagnosis of CTD-ILD or IPF and a UIP pattern on computed tomography and/or pathology were included in this study. Prevalence of 3 computed tomography findings shown to be associated with CTD-ILD (the straight edge sign [SES], the exuberant honeycombing sign, and the anterior upper lobe sign [AULS]) were tabulated in CTD-ILD and IPF subjects. The ability of each of these signs to discriminate between CTD-ILD and IPF was evaluated. Survival analysis was also performed using log-rank analysis. RESULTS The study cohort included 50 CTD-ILD and 100 IPF subjects with UIP. The SES and the AULS were more common in CTD-ILD than IPF (prevalence, 36.0% and 34.9% in CTD-ILD vs 8.3% and 17.2% in IPF, respectively [P = 0.0105
- Published
- 2021
40. The genomics of heart failure: design and rationale of the HERMES consortium
- Author
-
Svati H. Shah, Olle Melander, Neneh Sallah, Quinn S. Wells, Jerome I. Rotter, Faye Zhao, Charlotte Andersson, Guðmundur Thorgeirsson, Ghazaleh Fatemifar, Alex S. F. Doney, Michael E. Dunn, David E. Lanfear, Ian Ford, Eric Boersma, Sonia Shah, Christopher Newton-Cheh, Douglas L. Mann, Niek Verweij, Carolina Roselli, Laura M. Yerges-Armstrong, Jian Yang, Christian Torp-Pedersen, Veikko Salomaa, Mary L. Biggs, Alaa Shalaby, Christoph Nowak, Stefan Gross, Patrick T. Ellinor, Mari Liis Tammesoo, Diane T. Smelser, Peter M. Visscher, Hans L. Hillege, Ruth C. Lovering, Honghuang Lin, Colin N. A. Palmer, Louis Philippe Lemieux Perreault, Jeffrey Brandimarto, Uwe Völker, Perttu Salo, Andrea Koekemoer, Rebecca Gutmann, Åsa K. Hedman, Nilesh J. Samani, Heming Xing, Faiez Zannad, Jaison Jacob, Harry Hemingway, Michael R. Brown, Franco Giulianini, Anubha Mahajan, Xing Chen, Alexander Niessner, Peter Almgren, Daniel I. Swerdlow, Gunnar Engström, Lars Lind, Tõnu Esko, Tomasz Czuba, Anna Helgadottir, Harvey D. White, David J. Stott, Johan Ärnlöv, Lars Køber, Chim C. Lang, Krishna G. Aragam, Kent D. Taylor, Anders Mälarstig, Frederick K. Kamanu, Kenneth B. Margulies, Michelle L. O'Donoghue, Andrew D. Morris, Sahar Ghasemi, J. Wouter Jukema, Jessica van Setten, Abbas Dehghan, Guillaume Paré, Luca A. Lotta, Giorgio E. M. Melloni, Albert Henry, Bruce M. Psaty, Paul M. Ridker, David J. Carey, Marie-Pierre Dubé, John S. Gottdiener, Xiaosong Wang, Per H. Svensson, Xu Chen, Patrik K. E. Magnusson, Claudia Langenberg, Alexander Teumer, Vilmantas Giedraitis, Simon de Denus, Michael W. Nagle, Marcus Dörr, Thomas P. Cappola, André G. Uitterlinden, Michael Morley, Eliana Portilla-Fernandez, J. Gustav Smith, Abirami Veluchamy, Peter Weeke, Ify R. Mordi, Unnur Thorsteinsdottir, Naveed Sattar, Folkert W. Asselbergs, Daniel I. Chasman, Daníel F. Guðbjartsson, Jonathan H. Chung, Marcus E. Kleber, Raul Weiss, Christopher P. Nelson, Spiros Denaxas, Bing Yu, Simon P. R. Romaine, Nicholas A Marston, Anjali T. Owens, Cecilia M. Lindgren, John J.V. McMurray, Joshua D. Backman, Michael V. Holmes, Stella Trompet, Hilma Holm, Kerri L. Wiggins, Jian'an Luan, Stephan B. Felix, Yifan Yang, Jemma B. Wilk, Maryam Kavousi, Markus Perola, Christian T. Ruff, Jean-Claude Tardif, G Sveinbjörnsson, Samuel C. Dudley, Nicholas J. Wareham, Teemu J. Niiranen, Andrew P. Morris, Danny Tuckwell, Maris Teder-Laving, R. Thomas Lumbers, James P. Cook, Géraldine Asselin, William A. Chutkow, Winfried März, Steven A. Lubitz, John G.F. Cleland, Bill Kraus, Ramachandran S. Vasan, Christopher M. Haggerty, Olympe Chazara, Chris Finan, Heather L. Bloom, Hans-Peter Brunner-La Rocca, Francoise Fougerousse, Kenneth Rice, Craig L. Hyde, Graciela E. Delgado, Mark Chaffin, Marc S. Sabatine, Alanna C. Morrison, Kay-Tee Khaw, Kari Stefansson, Felix Vaura, Barry London, Isabella Kardys, Aroon D. Hingorani, Hongsheng Gui, Steen Stender, René Fouodjio, Mohsen Ghanbari, Pim van der Harst, Nicholas L. Smith, Karoline Kuchenbaecker, Adriaan A. Voors, Benoit Tyl, University College of London [London] (UCL), University College London Hospitals (UCLH), Boston University School of Medicine (BUSM), Boston University [Boston] (BU), Lund University [Lund], Pfizer, Karolinska Institutet [Stockholm], Broad Institute of MIT and Harvard (BROAD INSTITUTE), Harvard Medical School [Boston] (HMS)-Massachusetts Institute of Technology (MIT)-Massachusetts General Hospital [Boston], University of Groningen [Groningen], University of Oxford [Oxford], Dalarna University, Massachusetts General Hospital [Boston], Montreal Heart Institute - Institut de Cardiologie de Montréal, Regeneron Genetics Center, 777 Old Saw Mill River Road, Tarrytown, University of Washington [Seattle], Emory University [Atlanta, GA], Erasmus University Medical Center [Rotterdam] (Erasmus MC), University of Pennsylvania [Philadelphia], The University of Texas Health Science Center at Houston (UTHealth), Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], Department of Molecular and Functional Genomics, Geisinger, Danville, PA, Brigham & Women’s Hospital [Boston] (BWH), Harvard Medical School [Boston] (HMS), AstraZeneca, Novartis Institutes for BioMedical Research (NIBR), University of Glasgow, University of Liverpool, Université de Montréal (UdeM), Imperial College London, University of Heidelberg, Medical Faculty, University of Dundee, Universität Greifswald - University of Greifswald, University of Minnesota Medical School, University of Minnesota System, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Institut de Recherches Internationales Servier [Suresnes] (IRIS), Uppsala University, University of Maryland School of Medicine, University of Maryland System, University of Iceland [Reykjavik], deCODE genetics [Reykjavik], Henry Ford Hospital, Carver College of Medicine, University of Iowa, Geisinger Autism & Developmental Medicine Institute [Danville, PA, USA] (ADMI), ICIN - Netherlands Heart Institute, Leiden University Medical Center (LUMC), Netherlands Heart Institute, Partenaires INRAE, University of Cambridge [UK] (CAM), Rigshospitalet [Copenhagen], Copenhagen University Hospital, University of Leicester, Duke University [Durham], University of Iowa [Iowa City], Genentech, Inc., Genentech, Inc. [San Francisco], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), Skane University Hospital [Malmo], University of Edinburgh, Medizinische Universität Wien = Medical University of Vienna, University of Turku, National Institute for Health and Welfare [Helsinki], McMaster University [Hamilton, Ontario], Kaiser Permanente Washington Health Research Institute [Seattle] (KPWHRI), Harbor UCLA Medical Center [Torrance, Ca.], University Medical Center [Utrecht], University of Pittsburgh Medical Center [Pittsburgh, PA, États-Unis] (UPMC), University of Tartu, Aalborg University [Denmark] (AAU), Leiden University, University of Queensland [Brisbane], Ohio State University [Columbus] (OSU), Auckland City Hospital, GlaxoSmithKline, Glaxo Smith Kline, University of Texas Health Science Center, Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Duke University Medical Center, Regeneron Pharmaceuticals [Tarrytown], Vanderbilt University [Nashville], European Project, Langenberg, Claudia [0000-0002-5017-7344], Luan, Jian'an [0000-0003-3137-6337], Wareham, Nicholas [0000-0003-1422-2993], Apollo - University of Cambridge Repository, Cardiovascular Centre (CVC), Life Course Epidemiology (LCE), Groningen Kidney Center (GKC), Cardiology, University of Oxford, University of Pennsylvania, Universiteit Leiden, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - H02 Cardiomyopathy, Epidemiology, and Internal Medicine
- Subjects
Male ,Study Designs ,Cardiomyopathy ,Disease ,030204 cardiovascular system & hematology ,0302 clinical medicine ,AFRICAN ANCESTRY ,Epidemiology ,80 and over ,WIDE ASSOCIATION ,EPIDEMIOLOGY ,Cardiac and Cardiovascular Systems ,AGING RESEARCH ,RISK ,Aged, 80 and over ,0303 health sciences ,Kardiologi ,Genomics ,Middle Aged ,Prognosis ,3. Good health ,Female ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Heart failure ,CLASSIFICATION ,Heart Failure/genetics ,03 medical and health sciences ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Internal medicine ,Genetic model ,medicine ,Genetics ,Diseases of the circulatory (Cardiovascular) system ,Humans ,Allele frequency ,Genotyping ,METAANALYSIS ,030304 developmental biology ,Aged ,Association studies ,Study Design ,business.industry ,Odds ratio ,ADULTS ,COHORTS ,medicine.disease ,RC666-701 ,REPLICATION ,business ,Biomarkers ,Genome-Wide Association Study - Abstract
Aims The HERMES (HEart failure Molecular Epidemiology for Therapeutic targets) consortium aims to identify the genomic and molecular basis of heart failure.Methods and results The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34-90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of >1.10 for common variants (allele frequency > 0.05) and >1.20 for low-frequency variants (allele frequency 0.01-0.05) at P < 5 x 10(-8) under an additive genetic model.Conclusions HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.
- Published
- 2021
41. Radiologic Classification of Black Lung: Time for a New Gold Standard?
- Author
-
David A. Lynch, Jonathan H. Chung, Jeffrey P. Kanne, and Cristopher A. Meyer
- Subjects
Pulmonary and Respiratory Medicine - Published
- 2022
42. Early-stage COVID-19 pandemic observations on pulmonary embolism using nationwide multi-institutional data harvesting
- Author
-
Axel Wismüller, Adora M. DSouza, Anas Z. Abidin, M. Ali Vosoughi, Christopher Gange, Isabel O. Cortopassi, Gracijela Bozovic, Alexander A. Bankier, Kiran Batra, Yosef Chodakiewitz, Yin Xi, Christopher T. Whitlow, Janardhana Ponnatapura, Gary J. Wendt, Eric P. Weinberg, Larry Stockmaster, David A. Shrier, Min Chul Shin, Roshan Modi, Hao Steven Lo, Seth Kligerman, Aws Hamid, Lewis D. Hahn, Glenn M. Garcia, Jonathan H. Chung, Talissa Altes, Suhny Abbara, and Anna S. Bader
- Subjects
Health Information Management ,Medicine (miscellaneous) ,Health Informatics ,Computer Science Applications - Abstract
We introduce a multi-institutional data harvesting (MIDH) method for longitudinal observation of medical imaging utilization and reporting. By trackingbothlarge-scale utilizationandclinical imaging results data, the MIDH approach is targeted at measuring surrogates for important disease-related observational quantities over time. To quantitatively investigate its clinical applicability, we performed a retrospective multi-institutional study encompassing 13 healthcare systems throughout the United States before and after the 2020 COVID-19 pandemic. Using repurposed software infrastructure of a commercial AI-based image analysis service, we harvested data on medical imaging service requests and radiology reports for 40,037 computed tomography pulmonary angiograms (CTPA) to evaluate for pulmonary embolism (PE). Specifically, we compared two 70-day observational periods, namely (i) a pre-pandemic control period from 11/25/2019 through 2/2/2020, and (ii) a period during the early COVID-19 pandemic from 3/8/2020 through 5/16/2020. Natural language processing (NLP) on final radiology reports served as the ground truth for identifying positive PE cases, where we found an NLP accuracy of 98% for classifying radiology reports as positive or negative for PE based on a manual review of 2,400 radiology reports. Fewer CTPA exams were performed during the early COVID-19 pandemic than during the pre-pandemic period (9806 vs. 12,106). However, the PE positivity rate was significantly higher (11.6 vs. 9.9%,p −4) with an excess of 92 PE cases during the early COVID-19 outbreak, i.e., ~1.3 daily PE cases more than statistically expected. Our results suggest that MIDH can contribute value as an exploratory tool, aiming at a better understanding of pandemic-related effects on healthcare.
- Published
- 2021
43. Abstract
- Author
-
Z Lu, A. Sanchez, E. Marshall, Ingrid Reiser, Jonathan H. Chung, and C. Guo
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Medicine ,General Medicine ,business ,Virology - Published
- 2021
44. EVALUATING CLINICAL UTILITY OF A UIP GENOMIC CLASSIFIER IN SUBJECTS WITH AND WITHOUT A HRCT PATTERN OF UIP
- Author
-
Umair Gauhar, Karel Calero, Jeffrey L. Myers, Ganesh Raghu, David A. Lynch, Mark P. Steele, David J. Lederer, Murali Ramaswamy, Kevin K. Brown, Navdeep S. Rai, Amy Case, John M. Davis, Kevin R. Flaherty, Steve D. Groshong, Patric Walsh, Jing Huang, Neil M. Barth, Yoonha Choi, Fernando J. Martinez, Giulia C. Kennedy, Jonathan H. Chung, Thomas V. Colby, Lars Hagmeyer, Sadia Benzaquen, Hannah Neville, Brandon T. Larsen, Lori Lofaro, Steven D. Nathan, Daniel G. Pankratz, and Gerard J. Criner
- Subjects
Pulmonary and Respiratory Medicine ,business.industry ,Medicine ,Pattern recognition ,Artificial intelligence ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine ,business ,Classifier (UML) - Published
- 2019
45. COMBINING RADIOLOGY AND ENVISIA, A MOLECULAR CLASSIFIER, TO IMPROVE USUAL INTERSTITIAL PNEUMONIA (UIP) DIAGNOSIS
- Author
-
Sadia Benzaquen, Daniel G. Pankratz, Mark P. Steele, Ganesh Raghu, Neil M. Barth, Kevin K. Brown, Navdeep S. Rai, Brandon T. Larsen, Kevin R. Flaherty, Umair Gauhar, John M. Davis, Lars Hagmeyer, Steve D. Groshong, Karel Calero, Jeffrey L. Myers, Murali Ramaswamy, David J. Lederer, Patric Walsh, Thomas V. Colby, Fernando J. Martinez, Hannah Neville, Jing Huang, Steven D. Nathan, Jonathan H. Chung, Gerard J. Criner, Yoonha Choi, Giulia C. Kennedy, Amy Case, David A. Lynch, and Lori Lofaro
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Usual interstitial pneumonia ,business.industry ,medicine ,Radiology ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine ,medicine.disease ,business ,Classifier (UML) - Published
- 2019
46. ACR Appropriateness Criteria® Noninvasive Clinical Staging of Primary Lung Cancer
- Author
-
Barbara L. McComb, Expert Panel on Thoracic Imaging, Sue S. Yom, Stephen B. Hobbs, Mark F. Berry, Benjamin Movsas, Patrick M. Colletti, Brett W. Carter, Christopher M. Walker, Patricia M. de Groot, Jonathan H. Chung, Jeanne B. Ackman, Jeffrey P. Kanne, and Betty C. Tong
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Large cell ,medicine.disease ,Appropriate Use Criteria ,respiratory tract diseases ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Carcinoma ,Adenocarcinoma ,Radiology, Nuclear Medicine and imaging ,Stage (cooking) ,Lung cancer staging ,Lung cancer ,business ,Grading (tumors) - Abstract
Lung cancer is the leading cause of cancer-related deaths in both men and women. The major risk factor for lung cancer is personal tobacco smoking, particularly for small-cell lung cancer (SCLC) and squamous cell lung cancers, but other significant risk factors include exposure to secondhand smoke, environmental radon, occupational exposures, and air pollution. Education and socioeconomic status affect both incidence and outcomes. Non–small-cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, comprises about 85% of lung cancers. SCLC accounts for approximately 13% to 15% of cases. Prognosis is directly related to stage at presentation. NSCLC is staged using the eighth edition of the tumor-node-metastasis (TNM) criteria of the American Joint Committee on Cancer. For SCLC the eighth edition of TNM staging is recommended to be used in conjunction with the modified Veterans Administration Lung Study Group classification system distinguishing limited stage from extensive stage SCLC. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
- Published
- 2019
47. Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation
- Author
-
Imre Noth, Kiran H. Thakrar, Aliya N. Husain, Ayodeji Adegunsoye, Jonathan H. Chung, Steven M. Montner, Justin M. Oldham, Uday K. Mehta, Shashi Bellam, Wesley Klejch, Anne I. Sperling, Rekha Vij, Mary E. Strek, Paul Nolan, Janelle Vu Pugashetti, Catherine A. Bonham, Cara L. Hrusch, and Christopher M. Straus
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Lymphadenopathy ,Computed tomography ,Critical Care and Intensive Care Medicine ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Pulmonary fibrosis ,Mediastinal Diseases ,medicine ,Humans ,In patient ,030212 general & internal medicine ,medicine.diagnostic_test ,business.industry ,Interstitial lung disease ,Original Articles ,respiratory system ,medicine.disease ,respiratory tract diseases ,body regions ,030228 respiratory system ,Mediastinal lymph node ,Lymph Nodes ,Radiology ,Lung Diseases, Interstitial ,business ,Cohort study - Abstract
Rationale: Mediastinal lymph node (MLN) enlargement on chest computed tomography (CT) is prevalent in patients with interstitial lung disease (ILD) and may reflect immunologic activation and subsequent cytokine-mediated immune cell trafficking. Objectives: We aimed to determine whether MLN enlargement on chest CT predicts clinical outcomes and circulating cytokine levels in ILD. Methods: MLN measurements were obtained from chest CT scans of patients with ILD at baseline evaluation over a 10-year period. Patients with sarcoidosis and drug toxicity–related ILD were excluded. MLN diameter and location were assessed. Plasma cytokine levels were analyzed in a subset of patients. The primary outcome was transplant-free survival (TFS). Secondary outcomes included all-cause and respiratory hospitalizations, lung function, and plasma cytokine concentrations. Cox regression was used to assess mortality risk. Outcomes were assessed in three independent ILD cohorts. Measurements and Main Results: Chest CT scans were assessed in 1,094 patients (mean age, 64 yr; 52% male). MLN enlargement (≥10 mm) was present in 66% (n = 726) and strongly predicted TFS (hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.12–2.10; P = 0.008) and risk of all-cause and respiratory hospitalizations (internal rate of return [IRR], 1.52; 95% CI, 1.17–1.98; P = 0.002; and IRR, 1.71; 95% CI, 1.15–2.53; P = 0.008, respectively) when compared with subjects with MLN 45 pg/ml predicted mortality (HR, 4.21; 95% CI, 1.21–14.68; P = 0.024). Independent analysis of external datasets confirmed these findings. Conclusions: MLN enlargement predicts TFS and hospitalization risk in ILD and is associated with decreased levels of a key circulating cytokine, soluble CD40L. Incorporating MLN and cytokine findings into current prediction models might improve ILD prognostication.
- Published
- 2019
48. An Automated and Accurate Spine Curve Analysis System
- Author
-
Bo Chen, Jonathan H. Chung, Shuo Li, Qiuhao Xu, Liansheng Wang, and Stephanie Leung
- Subjects
General Computer Science ,Computer science ,02 engineering and technology ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Robustness (computer science) ,0202 electrical engineering, electronic engineering, information engineering ,General Materials Science ,business.industry ,Deep learning ,General Engineering ,deep learning ,direct estimation ,CobB ,AEC-Net ,Regression ,high-precision calculation ,Nonlinear system ,020201 artificial intelligence & image processing ,Artificial intelligence ,lcsh:Electrical engineering. Electronics. Nuclear engineering ,Error detection and correction ,business ,Cobb angle estimation ,Algorithm ,lcsh:TK1-9971 - Abstract
We present a new Adaptive Error Correction Net (AEC-Net) to formulate the estimation of Cobb anges from spinal X-rays as a high-precision regression task. Our AEC-Net introduces two novel innovations. (1) The AEC-Net contains two networks calculating landmarks and Cobb angles separately, which robustly solve the disadvantage of ambiguity in X-rays since these networks focus on more features. It effectively handles the nonlinear relationship between input images and quantitative outputs, while explicitly capturing the intrinsic features of input images. (2) Based on the two estimated angles, the AEC-Net proposed a new loss function to calculate the final Cobb angles. The optimization of the loss function is based on a high-precision calculation method. The deep learning structure is used to complete this optimization, which achieves higher accuracy and efficiency. We validate our method with the spinal X-rays dataset of 581 subjects with signs of scoliosis at varying extents. The proposed method achieves high accuracy and robustness on the Cobb angle estimations. Comparing to the exsiting conventional methods suffering from tremendous variability and low reliability caused by high ambiguity and variability around boundaries of the vertebrae, the AEC-Net obtain Cobb angles accurately and robustly, which indicates its great potential in clinical use. The highly accurate Cobb angles produced by our framework can be used by clinicians for comprehensive scoliosis assessment, and possibly be further extended to other clinical applications.
- Published
- 2019
49. Proximal Interruption of the Pulmonary Artery
- Author
-
Eric A. Williams, Rolf Grage, Jonathan H. Chung, Chad Cox, and Carlos A. Rojas
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,medicine.diagnostic_test ,biology ,business.industry ,Pipa ,Magnetic resonance imaging ,Perfusion scanning ,030204 cardiovascular system & hematology ,biology.organism_classification ,Asymptomatic ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,medicine.artery ,Pulmonary artery ,Pulmonary angiography ,Medicine ,Radiology, Nuclear Medicine and imaging ,Developmental anomaly ,Radiology ,Presentation (obstetrics) ,medicine.symptom ,business - Abstract
Proximal interruption of the pulmonary artery (PIPA) is an uncommon developmental anomaly resulting in underdevelopment of the proximal portion of the pulmonary artery with preservation of the intrapulmonary segments. Clinical presentation ranges between an asymptomatic incidental finding to massive hemoptysis. When findings suggestive of PIPA are present radiographically, the diagnosis of PIPA can be definitively diagnosed with computed tomography or magnetic resonance pulmonary angiography. Other imaging modalities, such as nuclear perfusion scan and catheter angiography can help in the diagnosis.
- Published
- 2019
50. Congenital Thoracic Aortic Disease
- Author
-
Luis Landeras and Jonathan H. Chung
- Subjects
medicine.medical_specialty ,Computed Tomography Angiography ,Sedation ,Aortic Diseases ,Contrast Media ,Aorta, Thoracic ,Computed tomography ,Asymptomatic ,030218 nuclear medicine & medical imaging ,Imaging modalities ,03 medical and health sciences ,0302 clinical medicine ,medicine.artery ,medicine ,Humans ,Thoracic aorta ,Radiology, Nuclear Medicine and imaging ,Thoracic aortic disease ,medicine.diagnostic_test ,business.industry ,General Medicine ,030220 oncology & carcinogenesis ,Embryology ,Angiography ,Radiology ,medicine.symptom ,business - Abstract
Congenital abnormalities of the thoracic aorta encompass a variety of disorders with variable clinical manifestations ranging from asymptomatic to life threatening. A variety of imaging modalities are available for the evaluation of these anomalies with computed tomography (CT) commonly preferred due to its excellent spatial resolution and rapid acquisitions, avoiding the need of general anesthesia or even sedation. We review the embryology, imaging findings, and associations of multiple congenital thoracic aorta malformations with emphasis in the role of CT angiography in the evaluation of these pathologies.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.